We Claim

~~CLAIMS~~:

1. A pharmaceutical formulation for oral administration comprising a) an HIV protease inhibitor and b) a water soluble tocopherol derivative in a ratio of from about 1:0.5 to about 1:10 w/w.

2. A pharmaceutical formulation for oral administration comprising (a) an HIV protease inhibitor and (b) at least 20% of a water soluble tocopherol derivative in the absence of a lipophilic phase.

3. A pharmaceutical formulation for oral administration comprising (a) an HIV protease inhibitor and (b) at least 20% of a water soluble tocopherol derivative wherein the ratio of (a) to (b) is from about 1:0.5 to about 1:10 w/w.

4. A pharmaceutical formulation for oral administration comprising (a) an HIV protease inhibitor (b) a water soluble tocopherol derivative and (c) a hydrophilic non-aqueous solvent miscible with said water soluble tocopherol derivative wherein the ratio of (a) to (b) is from about 1:0.5 to about 1:10 w/w.

5. A pharmaceutical formulation as claimed in claim 4 comprising at least 20% of a water soluble tocopherol derivative.

6. A pharmaceutical formulation as claimed in any preceding claim wherein the ratio of (a) to (b) is from about 1:0.5 to about 1:1.3 w/w.

7. A pharmaceutical formulation as claimed in any preceding claim wherein the water soluble tocopherol derivative is Vitamin E-TPGS.

8. A pharmaceutical formulation as claimed in any one of claims 4 to 7 wherein the hydrophilic non-aqueous solvent is a polyethylene glycol, propylene glycol or polyvinyl pyrrolidone.

9. A pharmaceutical formulation for oral administration consisting essentially of (a) an HIV protease inhibitor (b) Vitamin E-TPGS (c) polyethylene glycol and (d) propylene glycol.

10. A pharmaceutical formulation as claimed in any preceding claim wherein the HIV protease inhibitor is 3S-[3R*(1R*, 2S*)]-[3-[[(4-amino-phenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]-carbamic acid, tetrahydro-3-furanyl ester.

11. A formulation as claimed in any preceding claim present in the form of a capsule.

12. A method of preparing a formulation as claimed in any preceding claim which method comprises dissolving an HIV protease inhibitor in a water soluble tocopherol derivative.

13. A Pharmaceutical formulation substantially as herein described with reference to the foregoing examples.

14. A method of preparing a formulation substantially as hereinbefore described with reference to the foregoing examples.

Dated this 21st day of March, 1997.

(B. KOMBI)
OF REMFRY & SAGAR
ATTORNEY FOR THE APPLICANTS